Sacituzumab Tirumotecan Combo Extends PFS in PD-L1-Negative NSCLC

A phase 3 randomized trial compared sacituzumab tirumotecan plus pembrolizumab against chemotherapy plus pembrolizumab as first-line treatment in patients with PD-L1-negative advanced nonsquamous NSCLC without targetable genomic alterations. The trial reported significantly longer median progression-free survival with the sacituzumab tirumotecan combination (15.0 months vs. 5.7 months; hazard ratio 0.49), with fewer grade 3 or higher adverse events (47.6% vs. 60.6%) though stomatitis was common, mostly grade 1 or 2; overall survival data remained immature at this interim analysis.

Most relevant for: Patients with previously untreated, PD-L1-negative advanced nonsquamous NSCLC lacking targetable genomic alterations.

Summary written by an AI model from the source text and dated by the source's publication date. Check the original before acting on it. How MedFollow selects and summarizes updates.

Informational only. Not medical advice. Not a substitute for clinical judgment. Always consult current guidelines and your own clinical judgment.